Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BB...you could always compare your earnings model with Jeffriies...would love to see the differences if you were willing to share!
Amarin Co. plc (NASDAQ:AMRN) – Equities researchers at Jefferies Financial Group dropped their FY2018 earnings per share estimates for Amarin in a report released on Wednesday, December 19th. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will post earnings per share of ($0.41) for the year, down from their prior estimate of ($0.34). Jefferies Financial Group has a “Buy” rating and a $30.00 price target on the stock. Jefferies Financial Group also issued estimates for Amarin’s Q4 2018 earnings at ($0.12) EPS, Q1 2019 earnings at ($0.12) EPS, Q2 2019 earnings at ($0.10) EPS, Q3 2019 earnings at ($0.10) EPS, Q4 2019 earnings at ($0.10) EPS, FY2019 earnings at ($0.42) EPS and FY2020 earnings at ($0.13) EPS.
Con capk ...reluctant to submit paperwork for off label. Thankyou for sharing...it’s been my feeling that off label and insurance coverage are major inhibitors in 2019. Others on the board are drinking koolaid by the gallon. Can’t believe mgmt wasn’t on top of sNDA submission beginning of Q4. Reminds me how they weren’t prepared for a negative adcom back in 2013....basic business 101...have a friggin backup plan Thero!
BB...no way am i drinking the same koolaid you and JL are. Wonder how you get a $100 pps when one if the biggest analysts for amarin is calling for negative earnings in 2019?
2019 eps fy (.42) same as FYI 2018 as forecasted by Jeffries? What am I missing?
Stockboy...even with existing FDA approvad label, insurance has been an issue in some form or another, whether it’s outright coverage or tier level. Your biggest patient population oppty is on Medicare and until expanded label...I don’t see exponential growth short term. So yes 3-4 years could be how much time it takes to see the 2b revenue market some are forecasting, as well as significant pps appreciation. Generics still continue to be the preferred drug by many carriers...whether it’s in the best interest of the patient or not. We need this FDA expanded label yesterday to have a rats ass chance to see exponential script growth in 2019, and getting it in 3Q or 4Q is late. As a long term holder, i’d Much prefer a 35-50$ buyoutnow, rather than the so called lotto prize of $100 to whatever sometime in the future
Webster...enjoyed the refreshing perspective of Gia...as I am in agreement as well. The idea of waiting another 3-4 years of business development is discouraging after waiting 6 years to get here. I don’t buy the idea that vasecpa sells itself as some have suggested on this board...and I really do think insurance will be an ongoing issue.
Humptytrympy sat on a wall....and well i think it ends like our amrn stock for the time being...
Thero...must think its the quiet period...
Cmon JL...i too remember you crying about having to sell 15k shares of Amarin instead of only 5k to pay for your new nsx on order in January...and to boot, you were quite worried for your son who had bought a lot on margin! GLTA!
Social...pretty sure the board has a lot of say in this as well....
Whal...i call it like I see it. Can’t help but feel the stock would be close to it’s all time highs if it weren’t for a down market overall....
JL...no worries! My 2nd worst fear all these years was that after a successful R-IT, we would enter in to a bear market...and here we are.
JL, your comments can be quite confusing...when I asked about insurance coverage you sounded like it was a no brained...and now? Quote “biowreck
Quote: "what’s your thoughts on insurance coverage for off label scripts, hasn’t been a problem for me but as a doc, do you think it is of any significance?"
The NNT for this drug on hard MACE is 21...That means you need to treat 21 patients to get a CVD MACE benefit in one patient. ...To put this into perspective the NNT for statins is 104...Meaning....well you get the point....
This is the kind of data insurance companies look at for cost effectiveness...The final results are not in...but 21 is a very impressive number...
":>) JL
Pof...yeah but you get what you pay for
The key issue is whether or not payers will readily cover Vascepa as an add-on to statin therapy prior to a formal approval from U.S. regulators. Why are you stalling JT?
ILove...yes $23 on euphoria...as we all experienced after years of agony. But one thing seems to hold true...not a lotta love for Amarin by ws. We are still in prove it to me stage...dont care bout the rah rah statistics. So the question is, how long does it take to prove it to me...either by bo or scripts. Without FDA approval, I don’t think scripts will be nearly as robust as they could be...and I say this because of greedy insurance companies....
Simple...no FDA approval for expanded label....while mgmt sits on the laurels getting ready for early 2019 submission. Bout as brilliant a move as not having a backup plan for a negative adcom...
Amazing predictions Marzan...simply amazing.
AnonyF...so you’re saying the stock could go up or down?
So John Thero...why no sNDA till next year? Why after waiting 7 years for R-IT to complete, would you not had an sNDA submitted Sept 24th? And please, don’t evade the question like you did on Bloomberg regarding the secondary!
Invest8....thero was asked point blank about raising more cash thru a po...he eluded the question by saying that he told the shareholders that the last raise was for expansion andnmarketing and then said future revenues would also allow them to continue operations and r-it trial was over freeing up expense. It was obvious he was skirting the question...but you want to believe in the guy...but this is horsepoop
Bout...new fda approval process...if management Iis delaying sNDA to early 2019...then new process won’t work until then.
BT...it’s the blame game as usual. Same whiners forget how JT and staff have steered this company thru the years eventually leading a landmark win against the omnipotent FDA. Sales have tripled in two years against a generic company with a small patient population. Just because things didn’t go the way some planned for their long awaited fortunes doesn’t mean things won’t work out for us. Bummed that we have to wait longer for catalysts such as exponential script counts and earnings, or possible buyout...but I have faith in JT’s direction and strategy. Execution is key...so far so good. If we all truly measured Amarin’s success by how many lives are saved or improved instead of pps performance we might be rewarded by a power much greater than our own.....
MarkiP...quote pps goin nowhere. Unless a buyout gets announced, im thinking its gonna be about earnings now...so not expecting much till Q2 2019...and bummed about that....
BB ...I’m in the same camp...where is the friggin FDA?
JL....my point regarding FDA is that since they are the ones that helped and approved the design of the trial, the placebo concern could possibly be put to bed by them weighing in...if that was thru an sNDA or other means it would finish off this obstacle to pps going higher. If 85% of cardio docs say yes, the FDA says yes then explanation of moa is not necessary to refute bear thesis. You’ve been on the Gia bandwagon, which to reach the pps levels you envision, is going to take some time....so I’m surprised by your worries
Let me know how hat works out for ya yoyi
JL...so is the MO concern by some an issue for the FDA? Do we get the expanded label once sNDA is submitted? I don’t trust the FDA...and if they failed us....it would be the ultimate sham....
Heck if I was on statins i’d Be willing to test your hypothesis regarding mo on myself...could be interesting short of a 400 person trial.
Baa...gonna need that in euros please, possibly iin sterling lol.
Stac...yellow journalism at its finest. Blows my mind that AF and MH and these hack writers on SA can get away with their bs...love that American college of cardiology is weighing in. Wonder if the 85% of docs surveyed are scooping up shares....
Thanks JL...good to know
JL...what’s your thoughts on insurance coverage for off label scripts, hasn’t been a problem for me but as a doc, do you think it is of any significance?
Foodie...you still have the massive problem of naked shorting...
Perception...definitely hurt us today regardless of mineral oil inertness argument. Seemed well planned by our adversaries....so it bought them some time, but hopefully not enough as script count will be the only thing that silence the critics....that and perhaps a timely buyout.
Agree with James, pyrr is a wanna be and starved for attn. easier to place on ignore that see his rambling posts
Adam Fartstain...hopefully not on Vascepa.....
Jason, if their ever was a thorn in FDA’s side, you are definitely it lol. I think most on this board over the years recognize your passion...and sometimes madness :)
BB, why just a couple weeks ago there were a handful on this board saying the FDA is our friend....